Dual and Selective Actions of Glucocorticoids upon Basal and Stimulated Growth Hormone Release in Man
The DOI matches its Crossref record.
Abstract
In humans, corticoids suppress growth and growth hormone (GH) secretion elicited by a variety of stimuli, while in the rat they potentiate both in vivo and in vitro GH release. To further study this problem, growth-hormone-releasing hormone (GHRH) tests were performed in 6 nonobese Cushing’s syndrome patients and 6 controls. The normal GHRH-induced GH secretion was completely abolished in the Cushing’s syndrome group. To study the action of shorter corticoid exposures, 34 volunteers were subjected to four tests each: placebo treatment (control); dexamethasone (Dex) administration 4 mg i.v., 3 h before; Dex 8 mg p.o., 12 h before, and Dex 22 mg p.o. over the 2 days before the pituitary challenge that was always administered at 0 min (12.00 h). In the first test (n = 9), GHRH (1 µg/kg i.v.) induced a GH peak of 14.5 ± 3.8 ng/ml (control) that was potentiated by Dex 4 mg i.v. administered 3 h before (26.4 ± 6.8 ng/ml). On the contrary, longer Dex treatments suppress GHRH-induced GH values (6.0 ± 1.1 ng/ml after Dex 8 mg and 1.8 ± 0.3 ng/ml after Dex 22 mg). Clonidine administration 300 µg p.o. (n = 7) increased GH secretion with an area under the secretory curve (AUC) of 1,274 ± 236 that was potentiated by Dex 4 mg i.v. given 3 h before clonidine (2,380 ± 489) and reduced by Dex 8 mg, the reduction being significant only after 22 mg Dex(595 ± 47). When arginine 30 g was used as pituitary challenge (n = 6), the GH peak (19.1 ± 4.8 ng/ml) and the AUC (1,318 ± 322) were not significanty altered by Dex 4 mg nor by Dex 8 mg, but clearly reduced after pretreatment with Dex 22 mg (11.1 ± 4.6 ng/ml peak; 635 ± 189 AUC). The action of Dex was rather selective for GH secretion, because it did not alter (n = 6) prolactin, luteinizing hormone and follicle-stimulating hormone stimulated by a combined administration of luteinizing-hormone-releasing hormone and thyrotropin-releasing hormone. In this group, thyrotropin was only altered after the higher (22 mg) Dex treatment. These results showed a dual action of Dex on GH release in man. Short-term treatment potentiated basal and GHRH-stimulated GH secretion. The stimulatory action of corticoids becomes an inhibitory one when longer treatments are employed, suggesting, though not proving, to be mediated by somatostatin release from the hypothalamus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Cited by
Items 101–114 of 114
Bilateral adrenalectomy as treatment for Cushing's disease
Kemink, S. A. G. (2003) · Radboud Repository (Radboud University)
Diagnosis of Growth Hormone Deficiency
Fisker, S., Andersen, M., & Ørskov, H. (2005) · KARGER eBooks · doi:10.1159/000088417
Cushing's Syndrome : hormonal secretion patterns, treatment and outcome
van Aken, & Otto, M. (2005)
Losa, M., Arosio, M., Cusin, A., Biella, O., Palmieri, E., Faglia, G., & Giovanelli, M. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02466.x
Huijsman, M. (2003) · RePub (Erasmus University Rotterdam)
Galanin and the control of growth hormone secretion in man
Gilbey, S. G., O'Halloran, D. J., & Bloom, S. R. (1991) · doi:10.1007/978-1-349-12664-4_26
Luis, P., & Manuel, J. (2016) · RIULL (Universidad de La Laguna)
Corrales-Hlinka, M. F. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Pestana, F. M. (2010) · Americanae (AECID Library)
Kortisol-Reaktivität bei Personen mit sozialer Phobie vor und nach einer Online-Gruppentherapie
Morgenthal, P. (2025) · Gutenberg Open Science · doi:10.25358/openscience-14846
Metadata
- Authors
- Burguera, B., Muruais, C., Peñalva, A., Dieguez, C., & Casanueva, F. F.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2008-04-03
- Volume
- 51
- Issue
- 1
- Pages
- 51-58
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W1993558710
- Cited by
- 104
- References
- 0
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2019: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 3
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- glucocorticoids, growth hormone secretion, dexamethasone, Cushing's syndrome, clonidine, arginine stimulation, pituitary stimulation, growth hormone suppression, dose-dependent effects, pituitary-adrenal axis, growth hormone excess, growth hormone resistance
- MeSH terms
- Adult, Arginine, Clonidine, Cushing Syndrome, Dexamethasone, Female, Humans, Male, Metyrapone, Prolactin, Growth Hormone, Growth Hormone-Releasing Hormone, Thyrotropin, Thyrotropin-Releasing Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.